Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 495

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Open Targets Platform: supporting systematic drug–target identification and prioritisation

Open access
Ochoa, David, Hercules, Andrew, Carmona, Miguel, Suveges, Daniel, Gonzalez-Uriarte, Asier, Malangone, Cinzia, Miranda, Alfredo, Fumis, Luca, Carvalho-Silva, Denise, Spitzer, Michaela, Baker, Jarrod, Ferrer, Javier, Raies, Arwa, Razuvayevskaya, Olesya, Faulconbridge, Adam, Petsalaki, Eirini, Mutowo, Prudence, Machlitt-Northen, Sandra, Peat, Gareth, McAuley, Elaine, Ong, Chuang Kee, Mountjoy, Edward, Ghoussaini, Maya, Pierleoni, Andrea, Papa, Eliseo, Pignatelli, Miguel, Koscielny, Gautier, Karim, Mohd, Schwartzentruber, Jeremy, Hulcoop, David G, Dunham, Ian, McDonagh, Ellen M·2021·Nucleic Acids Research

Abstract

The Open Targets Platform (https://www.targetvalidation.org/) provides users with a queryable knowledgebase and user interface to aid systematic target identification and prioritisation for drug discovery based upon underlying evidence. It is publicly available and the underlying code is open source. Since our last update two years ago, we have had 10 releases to maintain and continuously improve evidence for target–disease relationships from 20 different data sources. In addition, we have integrated new evidence from key datasets, including prioritised targets identified from genome-wide CRISPR knockout screens in 300 cancer models (Project Score), and GWAS/UK BioBank statistical genetic analysis evidence from the Open Targets Genetics Portal. We have evolved our evidence scoring framework to improve target identification. To aid the prioritisation of targets and inform on the potential impact of modulating a given target, we have added evaluation of post-marketing adverse drug reactions and new curated information on target tractability and safety. We have also developed the user interface and backend technologies to improve performance and usability. In this article, we describe the latest enhancements to the Platform, to address the fundamental challenge that developing effective and safe drugs is difficult and expensive.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gkaa1027

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 495

Metadata

Authors
Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Gonzalez-Uriarte, A., Malangone, C., Miranda, A., Fumis, L., Carvalho-Silva, D., Spitzer, M., Baker, J., Ferrer, J., Raies, A., Razuvayevskaya, O., Faulconbridge, A., Petsalaki, E., Mutowo, P., Machlitt-Northen, S., Peat, G., McAuley, E., Ong, C. K., Mountjoy, E., Ghoussaini, M., Pierleoni, A., Papa, E., Pignatelli, M., Koscielny, G., Karim, M., Schwartzentruber, J., Hulcoop, D. G., Dunham, I., & McDonagh, E. M.
Venue
Nucleic Acids Research
Published
2020-11-16
Volume
49
Issue
D1
Pages
D1302-D1310
ISSN
  • 0305-1048 (ISSN-L)
  • 1362-4962
OpenAlex
W3106143834
Cited by
495
References
38
FWCI
29.66
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Open Targets Platform: supporting systematic drug–target identification and prioritisation. https://app.cochat.ai/papers/10.1093/nar/gkaa1027
The paper
Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Gonzalez-Uriarte, A., Malangone, C., Miranda, A., Fumis, L., Carvalho-Silva, D., Spitzer, M., Baker, J., Ferrer, J., Raies, A., Razuvayevskaya, O., Faulconbridge, A., Petsalaki, E., Mutowo, P., Machlitt-Northen, S., Peat, G., . . . McDonagh, E. M. (2021). Open Targets Platform: supporting systematic drug–target identification and prioritisation. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaa1027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.